NCT06775275View on ClinicalTrials.gov

A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2029

Conditions
Resectable Lung Non-Small Cell Carcinoma
Interventions
DRUG

Adebellizumab

adebrelimab

DRUG

Bevacizumab

bevacizumab

DRUG

Platinum-based chemotherapy

paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.

Trial Locations (1)

Unknown

RECRUITING

Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Guangzhou Medical University

OTHER